Swift Transportation (SWFT) Nearing Double Top Levels With WESCO International (WCC), Alimera Sciences (ALIM), Insight Enterprises (NSIT)

Swift Transportation Co. (SWFT) Thursday declared first-quarter profit of $12.3 million or $0.09 per share, down from $30.3 million or $0.21 per share in the same period last year. Adjusted earnings for the quarter was $0.12 per share, down from $0.24 per share in the prior year quarter. On average, 17 analysts polled by Thomson Reuters possible the company to earn $0.12 per share for the quarter. Swift Transportation Company (NYSE:SWFT), Trucking, is currently trading at $25.48, which thrived 1.80%. The stock is trading -4.61% below its 52-week high and 75.36% above its 52-week low. At the closing bell, shares in Swift Transportation Company recorded a trading volume of 1127500. Its total outstanding shares are 141.20 million with the market capitalization of $3597.78 million. SWFT showed -1.62% weekly performance. Experts rate it a ‘Buy’ stock.

Wesco International Inc (WCC) Thursday reported that Wesco Distribution Inc has completed the acquisition of Hi-Line Utility Supply, a giver of utility MRO and safety products, as well as rubber goods testing and certification services. Wesco expects the deal to be accretive to earnings by covering $0.03 per share in the first year of operation. Wesco International offers electrical, industrial, and communications MRO and OEM products, construction materials, and advanced supply chain management and logistics services. WESCO International Inc. (NYSE:WCC), Industrial Equipment Wholesale, is currently trading at $90.78, which soared 0.89%. The stock is trading -2.46% below its 50 days high and 8.74% above its 50 days low. Market capitalization of WESCO International Inc. is worth nearly $4034.26 million. The stock is currently trading at a P/E multiple of 19.65x with 1.54x PEG Ratio. WCC showed -1.89% weekly performance. Analysts rate it a ‘Buy’ stock.

Alimera Sciences, Inc. (ALIM), a biopharmaceutical company specializing in prescription ophthalmic pharmaceuticals, Monday notified that FDA has acknowledged the resubmission of its new drug application for Iluvien and has established September 26 as the Prescription Drug User Fee Act, or PDUFA, date. Iluvien is an intravitreal implant for the treatment of vision impairment linked with chronic diabetic macular edema (DME). The price of Alimera Sciences, Inc. (NASDAQ:ALIM), Drug Manufacturers – Major company, stock collapsed -1.78% to $6.07. The stock is dealing at -28.08% below its 52-week high and 267.88% above its 52-week low. The RSI of stock currently approaches at the level of 59.22 with 4.77% weekly volatility. The firm maintained its -$1.76 EPS for the stock. ALIM showed 145.75% half yearly performance. Experts rate it a ‘Buy’ stock.

Insight Enterprises Inc. (NSIT) reported first quarter non-GAAP EPS of $0.28 following the close Thursday, up from $0.24 in the prior year period. The consensus estimate was for EPS of $0.29. For the full year of 2014, the company continues to aim EPS of $1.97 to $2.07. Analysts anticipate EPS of $2.03. Insight Enterprises spiked to the upside in early trade Friday, but settled into a range for the majority of the session. The price of Insight Enterprises Inc. (NASDAQ:NSIT), Application Software company, stock flourished 0.38% to $28.82. The stock is dealing at -1.74% below its 52-week high and 70.94% above its 52-week low. Market capitalization of Insight Enterprises Inc. is worth nearly $1179.60 million. The stock is currently trading at a P/E multiple of 16.76x with 1.12x PEG Ratio. NSIT showed 2.09% weekly performance. We recommend to ‘Hold’ the stock.

About

Jennifer McKinney, CFA, is an equity analyst for The Downtown Leader. If you have a great story idea for Jennifer McKinney, you can write at [Jennifer.McKinney@downtownleader.com ].

POST YOUR COMMENTS